Last reviewed · How we verify
Triciribine
Triciribine is a Small molecule drug developed by Prescient Therapeutics, Ltd.. It is currently in discontinued development. Also known as: triciribine phosphate monohydrate, TCN, TCN-PM, AKT inhibitor.
Triciribine is a small molecule drug being studied in early stage clinical trials for breast cancer, specifically in conditions such as breast adenocarcinoma, estrogen receptor positive, HER2/neu negative, recurrent breast carcinoma, and stage IIB breast cancer. The trials involve combination therapies with cyclophosphamide and doxorubicin hydrochloride, and are analyzing laboratory biomarkers.
At a glance
| Generic name | Triciribine |
|---|---|
| Also known as | triciribine phosphate monohydrate, TCN, TCN-PM, AKT inhibitor, TCN-PM, BD-0002 |
| Sponsor | Prescient Therapeutics, Ltd. |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | discontinued |
Approved indications
Common side effects
Key clinical trials
- A Phase 2a, Double-Blind, Placebo-Controlled Study TCN 032 (Human Monoclonal Antibody Directed Against the M2 Protein of Influenza A Virus) in Subjects Challenged With H3N2 Influenza A Virus (Phase 2)
- A Phase I-II Study of Triciribine Phosphate Monohydrate (PTX-200) Plus Cytarabine in Refractory or Relapsed Acute Leukemia (Phase 1)
- Linking High-Risk Jail Detainees to HIV Pre-Exposure Prophylaxis: PrEP-LINK (NA)
- Comparative Effectiveness of Interventions to Increase Guideline-based Genetic Counseling in Ethnically and Geographically Diverse Cancer Survivors (NA)
- A Phase I Study of Triciribine Phosphate Monohydrate (TCN-PM, VD-0002) in Adult Patients With Advanced Hematologic Malignancies (Phase 1)
- A Phase IA/IB Trial of PTX-200 and Carboplatin in Patients With Platinum-Resistant Recurrent Ovarian Cancer (Phase 1)
- Transitions Clinic Network: Post Incarceration Addiction Treatment, Healthcare, and Social Support (NA)
- A Phase I-II Study of PTX-200 Plus Sequential Weekly Paclitaxel Followed by Dose-Dense Doxorubicin and Cyclophosphamide in Patients With Metastatic and Locally Advanced Breast Cancer (Phase 1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Triciribine CI brief — competitive landscape report
- Triciribine updates RSS · CI watch RSS
- Prescient Therapeutics, Ltd. portfolio CI
Frequently asked questions about Triciribine
What is Triciribine?
Who makes Triciribine?
Is Triciribine also known as anything else?
What development phase is Triciribine in?
Related
- Manufacturer: Prescient Therapeutics, Ltd. — full pipeline
- Therapeutic area: All drugs in Other
- Also known as: triciribine phosphate monohydrate, TCN, TCN-PM, AKT inhibitor, TCN-PM, BD-0002
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing